Medtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle
Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the LBBAP location show high defibrillation success
GALWAY, Ireland and SAN DIEGO, April 25, 2025 /PRNewswire/ — Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™ defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure™ Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement. The lead connects to an implantable defibrillator, and treats potentially life threatening ventricular tachyarrhythmias, ventricular fibrillation (VT/VF) and bradyarrhythmias. As the world's smallest defibrillation lead (4.7 French, or 1.6mm), the OmniaSecure lead represents a meaningful innovation in electrophysiology, and is indicated for stimulation in the right ventricle for adults and adolescent pediatric patients ages 12 and up, including those with smaller anatomies.
Separately, the company is also studying placing the novel, small-diameter OmniaSecure defibrillation lead in the left bundle branch (LBB) area, which has the potential to enable physiologic pacing to more closely mimic the heart's natural conduction system. Investigational outcomes of this study were presented at Heart Rhythm 2025 in San Diego. The results from the study demonstrate high defibrillation success of 100% at implant when the lead is implanted in the LBB area. Globally, the OmniaSecure defibrillation lead is investigational for use in LBB area and requires FDA approval in the future.
Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) are the standard for preventing sudden cardiac death. The ICD/CRT-D connects to a defibrillation lead (insulated electrical wire) that forms the electrical conduit between the device and the heart. The lead senses the heartbeat, and transmits signals to the implanted device, which then delivers therapy to correct or interrupt abnormally fast rhythms. The lead must flex with millions of heart contractions over a lifetime.
Existing defibrillation leads are larger in diameter than the OmniaSecure lead. A larger-diameter lead may increase the potential for downstream complications, such as venous occlusion or tricuspid valve regurgitation.
'FDA approval for the OmniaSecure defibrillation lead furthers our ability to offer physicians and patients a transvenous solution designed to be smaller to help minimize complications−including vascular complications and valve interaction−with strong, reliable lead durability. We engineered the OmniaSecure lead based on the trusted SelectSecure Model 3830 pacing lead, which has been the lead of choice for many physicians for more than 20 years,' said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. 'This milestone underscores our commitment to driving clinical innovations that help patients today while paving the way for future innovations that will usher in the next era of electrophysiology.'
Previously, researchers presented late breaking data from the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial showing the OmniaSecure defibrillation lead met its primary safety and effectiveness endpoints and exceeded prespecified performance goals when placed within the right ventricle. The results were presented during Heart Rhythm 2024, simultaneously published in Heart Rhythm, and are the basis of FDA approval for the traditional right ventricular lead placement indication.
Late-Breaking LEADR LBBAP Results Presented at Heart Rhythm 2025
Researchers presented late-breaking results at Heart Rhythm 2025 for the LEADR LBBAP (Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing) study that showed the OmniaSecure defibrillation lead demonstrated high defibrillation success when placed in the LBB area for patients indicated for an ICD or CRT-D. Placing the defibrillation lead in the LBB area is being evaluated as an alternative to right ventricular stimulation for sensing, pacing, cardioversion and defibrillation.
Defibrillation testing conducted in 162 patients at device implantation was successful in 100% of cases, with the study meeting the prespecified efficacy goal of 88%. Of the first 193 patients implanted in the study, the OmniaSecure lead was successfully implanted per protocol in 95.8% of the procedures as reported by physician investigators. There were no procedure-related major complications such as early helix or lead fracture, system revision, or death.
'The left bundle branch area is emerging as an option for more physiologic pacing for patients who receive an ICD or CRT-D to treat dangerous heart rhythms,' said Pugazhendhi Vijayaraman, M.D., cardiac electrophysiologist at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa., who presented the data at the meeting. 'The option to place a lead in the left bundle branch area may provide for physiologic pacing by engaging the heart's natural conduction system. These positive preliminary results for the LEADR LBBAP study are encouraging and highlight the potential versatility of the OmniaSecure defibrillation lead.'
The LEADR LBBAP trial is a global, prospective, non-randomized, multi-center study. The study has enrolled approximately 300 patients at 24 sites in 11 countries in North America, Europe, Asia and Australia. Patients enrolled in the study indicated for an ICD are being followed out to 3 months while patients indicated for CRT-D are being followed out to 6 months post-implant.
About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts: Joey LomickyPublic Relations+1-763-526-2494
Ryan WeispfenningInvestor Relations+1-763-505-4626
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
41 minutes ago
- Malaysian Reserve
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
SAN DIEGO, June 9, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. 'Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change,' said Matt Abernethy, Chief Financial Officer, Neurocrine Biosciences. 'As we launch CRENESSITY, grow INGREZZA, and advance our pipeline, he joins Neurocrine at an exciting time when advancements in technology will play a critical role in advancing our mission to help more patients.' 'I am excited to join Neurocrine at such a pivotal time for the company,' Choi said. 'I look forward to leveraging innovative IT and digital solutions to strengthen the business and support the teams who work tirelessly to discover, develop and deliver critical treatments for patients.' Choi joins Neurocrine after a 13-year career at Thermo Fisher Scientific, most recently as the Vice President of AI Automation & Data. Previously, he was Global Vice President of Digital Platforms, Engineering & Generative AI; Vice President of Digital Solutions for APAC and Emerging Markets; and Vice President of Corporate Solutions & Integrations. Prior to that, he held IT roles at Life Technologies (prior to its acquisition by Thermo Fisher Scientific), SysGroup Inc., Serene Corporation, ADP, and Corio, Inc. and earned a Bachelor of Arts degree at the University of California, Berkeley. About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit and follow the company on LinkedIn, X, and Facebook. (*in collaboration with AbbVie) NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. © 2025 Neurocrine Biosciences, Inc. All Rights Reserved. 06/2025
Malaysian Reserve
16 hours ago
- Malaysian Reserve
Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®
New collaboration delivers 50% off prescription sleep support for new customers who are struggling with insomnia and sleep disruption DALLAS, June 9, 2025 /PRNewswire/ — Health-E Commerce, the parent brand of FSA Store and HSA Store, the first and leading online stores dedicated to selling only FSA- and HSA-eligible products and services, announced today that it has expanded its telehealth collaboration with LifeMD™, a leader in virtual care. This latest initiative gives FSA and HSA users affordable, convenient access to FDA-approved prescription sleep treatments at a time when better sleep care is urgently needed. According to the CDC, insufficient sleep is linked to higher risks of obesity, diabetes, heart disease, and depression, which means expanded access to treatment is not just beneficial, it's essential. The arrangement allows new customers who shop at FSA Store or HSA Store to receive 50% off prescription sleep medications from LifeMD, with no in-person appointments required. Following a free virtual consultation, approved patients can have non-addictive, physician-prescribed treatments discreetly delivered to their door, making it easier than ever to address sleep concerns with clinically backed solutions. 'The connection between sleep and our overall physical and mental health is undeniable, and poor sleep can even impact our productivity at work and our overall quality of life,' said Keri Kaiser, chief revenue officer for Health-E Commerce. 'The expansion of our telehealth collaboration with LifeMD gives consumers more options for diagnosing and treating sleep disorders and improving sleep health, while saving money by using tax-free FSA- and HSA-eligible services. We're proud to simplify access to care for millions of Americans and to maximize their healthcare dollars.' Many individuals who experience poor sleep rely on over-the-counter remedies that may not be effective for persistent insomnia or sleep disruptions. Fortunately, LifeMD's prescription sleep solutions are designed to address the root causes of poor sleep with medications that target sleep onset, duration, and quality, including Ramelteon, Doxepin, and Trazodone. Eligibility for prescription treatments is determined by a licensed LifeMD physician and backed by LifeMD's 4.9-star patient satisfaction rating. 'We're proud to expand our telehealth collaboration with Health-E Commerce to give individuals and families who are enrolled in FSAs and HSAs access to clinical support to improve sleep health and their overall quality of life,' said Nicholas Alvarez, co-founder and chief acquisition & growth officer at LifeMD. 'Everyone deserves access to quality medical care that is convenient and affordable, and by collaborating with FSA Store and HSA Store, we are able to effectively extend the reach of our services to individuals and families across the country.' LifeMD's sleep solutions are now available at and alongside other telehealth services for home sleep apnea testing, CPAP devices and supplies, CPAP alternatives, and more. This launch reinforces Health-E Commerce's mission to make tax-free healthcare dollars work harder for the more than 70 million Americans enrolled in pre-tax health accounts. To learn more or access eligible sleep health services and products, visit or About Health-E CommerceHealth-E Commerce is the parent brand to FSA Store and HSA Store, online stores that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill®, a popular private-label line of health products through which a portion of every purchase is donated to the Children's Health Fund. Since 2010, the Health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in expanding eligibility for important new product and telehealth categories within the list of eligible medical expenses. About LifeMDLifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit
Malaysian Reserve
3 days ago
- Malaysian Reserve
NEDHSA to host JiggAerobics event
MONROE, La., June 6, 2025 /PRNewswire/ — Northeast Delta Human Services Authority (NEDHSA) is hosting its seventh JiggAerobics event beginning at 6 p.m. June 12 at Monroe Downtown River Market, 316 S. Grand St. NEDHSA Executive Director Dr. Monteic A. Sizer said the event provides a fun and upbeat activity for individuals of all ages and fitness levels. 'Fitness plays an important role in mental health and, when coupled with proper exercise, is a strong predictor of positive health outcomes,' Dr. Sizer said. 'By hosting events such as JiggAerobics, we are providing an opportunity for citizens of northeast Louisiana to engage in healthy activities and learn about the interconnectedness of their mental and physical health.' The event is part of NEDHSA's #getfitHSA initiative, which supports NEDHSA's integrated care model by increasing access to healthy activities and informing communities about the importance of staying fit and active. Data shows that heart disease, obesity and other physical illnesses are correlated with various forms of trauma, stress and mental illness, Dr. Sizer said. The event will be led by JiggAerobics founder LaDonte Lotts, also known as 'Mr. Get Right.' The dance-based fitness program fuses jigging — an energetic Louisiana dance style — with Lotts' dance moves and numerous plyometric exercises. NEDHSA consistently works to understand the unique health care needs of the citizens of Northeast Louisiana. 'Once we understand the needs and wishes of the people, we actively put programs and services in place to help meet people where they are,' Dr. Sizer said. Register for free tickets at
